Cargando…
A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer
OBJECTIVES: Lung cancer (LC) is often accompanied by significant methylation abnormalities. This study aimed to develop a decision tree (DT) accompanied the stature homeobox 2 gene (SHOX2) / prostaglandin E receptor 4 (PTGER4) gene DNA methylation with traditional tumor marker in the differential di...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791477/ https://www.ncbi.nlm.nih.gov/pubmed/33167712 http://dx.doi.org/10.1177/1073274820969703 |
_version_ | 1783633613457195008 |
---|---|
author | Huang, Wenhai Huang, Hao Zhang, Shuishen Wang, Xueping Ouyang, Juan Lin, Zhichao Chen, Peisong |
author_facet | Huang, Wenhai Huang, Hao Zhang, Shuishen Wang, Xueping Ouyang, Juan Lin, Zhichao Chen, Peisong |
author_sort | Huang, Wenhai |
collection | PubMed |
description | OBJECTIVES: Lung cancer (LC) is often accompanied by significant methylation abnormalities. This study aimed to develop a decision tree (DT) accompanied the stature homeobox 2 gene (SHOX2) / prostaglandin E receptor 4 (PTGER4) gene DNA methylation with traditional tumor marker in the differential diagnosis of benign and malignant lung nodule. METHODS: We performed a study with 104 patients enrolled in the LC group and 36 patients in the benign lung diseases group. All the clinical data of these patients were collected through electronic medical record. Total Methylation (TM) status of both SHOX2 and PTGER4 was defined as methylation levels of SHOX2 plus methylation levels of PTGER4. One-way analysis was used to compare the concentrations of serum samples and t-test was used to compare pairwise mean values between groups. Receiver operating curve (ROC) was used to evaluate the diagnostic value. Furthermore, the strategy was validated in 19 LC patients and 11 patients with benign lung diseases. RESULTS: There were significant differences between the concentration of neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA21 -1) and the methylation levels of SHOX2, PTGER4 and TM in lung benign diseases and cancer group. The AUCs of NSE, CEA, CYFRA21 -1, Methylation SHOX2, Methylation PTGER4 and TM were 0.721 (95% CI: 0.627–0.816), 0.753 (95% CI: 0.673–0.833) and 0.778(95% CI: 0.700–0.856), 0.851(0.786-0.916), 0.847(0.780-0.913) and 0.861(0.800-0.922) respectively. We developed a DT model with TM and CYFRA21 -1 used in this study, and the area under the curve (AUC) of DT was 0.921 and the sensitivity up to 0.856. In the validation cohort, the AUC of SHOX2, PTGER4 and TM was also much higher than traditional serum markers. CONCLUSIONS: Our results indicated that the DT model calculated from the TM and CYFRA21 -1 can accurately classify LC and benign diseases, which showed better diagnostic performance than traditional serum parameter. |
format | Online Article Text |
id | pubmed-7791477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-77914772021-04-09 A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer Huang, Wenhai Huang, Hao Zhang, Shuishen Wang, Xueping Ouyang, Juan Lin, Zhichao Chen, Peisong Cancer Control Original Research Paper OBJECTIVES: Lung cancer (LC) is often accompanied by significant methylation abnormalities. This study aimed to develop a decision tree (DT) accompanied the stature homeobox 2 gene (SHOX2) / prostaglandin E receptor 4 (PTGER4) gene DNA methylation with traditional tumor marker in the differential diagnosis of benign and malignant lung nodule. METHODS: We performed a study with 104 patients enrolled in the LC group and 36 patients in the benign lung diseases group. All the clinical data of these patients were collected through electronic medical record. Total Methylation (TM) status of both SHOX2 and PTGER4 was defined as methylation levels of SHOX2 plus methylation levels of PTGER4. One-way analysis was used to compare the concentrations of serum samples and t-test was used to compare pairwise mean values between groups. Receiver operating curve (ROC) was used to evaluate the diagnostic value. Furthermore, the strategy was validated in 19 LC patients and 11 patients with benign lung diseases. RESULTS: There were significant differences between the concentration of neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA21 -1) and the methylation levels of SHOX2, PTGER4 and TM in lung benign diseases and cancer group. The AUCs of NSE, CEA, CYFRA21 -1, Methylation SHOX2, Methylation PTGER4 and TM were 0.721 (95% CI: 0.627–0.816), 0.753 (95% CI: 0.673–0.833) and 0.778(95% CI: 0.700–0.856), 0.851(0.786-0.916), 0.847(0.780-0.913) and 0.861(0.800-0.922) respectively. We developed a DT model with TM and CYFRA21 -1 used in this study, and the area under the curve (AUC) of DT was 0.921 and the sensitivity up to 0.856. In the validation cohort, the AUC of SHOX2, PTGER4 and TM was also much higher than traditional serum markers. CONCLUSIONS: Our results indicated that the DT model calculated from the TM and CYFRA21 -1 can accurately classify LC and benign diseases, which showed better diagnostic performance than traditional serum parameter. SAGE Publications 2020-11-10 /pmc/articles/PMC7791477/ /pubmed/33167712 http://dx.doi.org/10.1177/1073274820969703 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Paper Huang, Wenhai Huang, Hao Zhang, Shuishen Wang, Xueping Ouyang, Juan Lin, Zhichao Chen, Peisong A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer |
title | A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and
Serum Biomarker for Early Stage Lung Cancer |
title_full | A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and
Serum Biomarker for Early Stage Lung Cancer |
title_fullStr | A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and
Serum Biomarker for Early Stage Lung Cancer |
title_full_unstemmed | A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and
Serum Biomarker for Early Stage Lung Cancer |
title_short | A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and
Serum Biomarker for Early Stage Lung Cancer |
title_sort | novel diagnosis method based on methylation analysis of shox2 and
serum biomarker for early stage lung cancer |
topic | Original Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791477/ https://www.ncbi.nlm.nih.gov/pubmed/33167712 http://dx.doi.org/10.1177/1073274820969703 |
work_keys_str_mv | AT huangwenhai anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT huanghao anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT zhangshuishen anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT wangxueping anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT ouyangjuan anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT linzhichao anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT chenpeisong anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT huangwenhai noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT huanghao noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT zhangshuishen noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT wangxueping noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT ouyangjuan noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT linzhichao noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer AT chenpeisong noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer |